David Cameron Reveals Prostate Cancer Diagnosis, Urges UK Screening Program
A former British Prime Minister has disclosed his recent treatment for prostate cancer, adding his prominent voice to a growing chorus of advocates calling for a national prostate cancer screening program in the United Kingdom. The announcement, made public this week, underscores the emotional toll of a cancer diagnosis and the importance of proactive health checks.
David Cameron, 59, shared his deeply personal experience with The Times, detailing the emotional toll of a cancer diagnosis and the importance of proactive health checks. He recounted the initial shock of a high prostate-specific antigen (PSA) test result, followed by the confirmation of cancer through a subsequent biopsy.
“You always hope for the best,” Cameron told the publication. “You have a high PSA score – that’s probably nothing. You have an MRI scan with a few black marks on it. You think, ‘Ah, that’s probably OK.’ But when the biopsy comes back, and it says you have got prostate cancer… You always dread hearing those words. And then literally as they’re coming out of the doctor’s mouth you’re thinking, ‘Oh, no, he’s going to say it. He’s going to say it. Oh God, he said it.'”
The impetus for Cameron to get tested came after his wife, Samantha, heard Soho House founder Nick Jones discuss his own diagnosis on the radio. He subsequently underwent focal therapy, a treatment utilizing electrical pulses to target and destroy cancer cells.
Cameron is now publicly advocating for a shift in national health policy. “I wont to, as it were, come out,” he stated. “I want to add my name to the long list of people calling for a targeted screening program.” he acknowledged the discomfort many men experience discussing their health, adding, “Let’s be honest. men are not very good at talking about their health. We tend to put things off.”
Prostate cancer affects approximately 55,000 men in the UK annually. Despite its prevalence, the UK remains an outlier among developed nations in its lack of a national screening program.This is largely due to concerns surrounding the accuracy of PSA tests, which can sometimes yield false positives, leading to unnecessary anxiety and invasive procedures.
The call for screening comes amidst a backdrop of other recent high-profile cancer diagnoses. In October 2024, six-time Olympic gold medallist Chris Hoy revealed his own terminal cancer diagnosis, with the disease having metastasized from his prostate to other areas of his body.
However, hope for change is on the horizon. Just days before Cameron’s announcement, the first eligible men in the UK were invited to participate in the Transform project, a major clinical trial evaluating the effectiveness of various screening techniques. The £16 million initiative, funded by the National Institute for Health and Care Research and Prostate Cancer UK, will compare new screening methods against current diagnostic processes, including blood tests and biopsies.
The launch of the Transform project coincides with the UK National Screening commitee’s impending decision on whether to recommend the introduction of a national screening program.
Chiara de Biase, director of health services, equity and advancement at Prostate Cancer UK, welcomed Cameron’s decision to share his story.”We’re glad to hear that David Cameron found his prostate cancer at an early stage and had prosperous treatment,” she said. “We thank him for sharing his story and in doing so raising vital awareness of this disease, which is completely curable if found early. But men’s lives should not be left to chance. We lose 12,000 dads,brothers,sons and friends to this disease every year. We’ve reached a tipping point in the UK, with too many men dying from a curable disease and worse outcomes for men at higher risk like black men and men from working-class communities.”
Cameron’s experience, coupled with the ongoing research and advocacy efforts, is intensifying the pressure on policymakers to address this critical public health issue and ensure earlier detection and improved outcomes for men across the UK.
